Glycomimetics INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Crescent Biopharma announced Q2 2026 financial results, highlighting progress in its clinical trials for CR-001, CR-002, and CR-003, and a strengthened cash position extending runway into late 2028.
Crescent Biopharma announced the pricing of its public offering of ordinary shares and pre-funded warrants, expecting to raise approximately $125 million.
Crescent Biopharma, Inc. announced preliminary unaudited financial information, estimating cash and cash equivalents of approximately $171.6 million as of June 30, 2026.
Crescent Biopharma, Inc. held its annual meeting on June 2, 2026, where shareholders elected directors, ratified the auditor, and approved executive compensation.
Crescent Biopharma announced its Q4 and full-year 2025 financial results, highlighting a strategic partnership with Kelun-Biotech, significant clinical trial advancements, and a $185 million private placement.
Crescent Biopharma announced a strategic partnership with Kelun-Biotech and a $185 million private placement to accelerate its oncology pipeline, including three programs entering clinical trials in 2026.
Crescent Biopharma announced its third quarter 2025 financial results and provided updates on its oncology pipeline, including progress for CR-001 and ADC programs.
Crescent Biopharma announced its second quarter 2025 financial results, highlighted pipeline progress for its oncology therapeutics, and approved a new executive severance plan.
Crescent Biopharma, Inc. has successfully completed its merger with GlycoMimetics, Inc. and a private financing round of $200 million, positioning the combined entity to accelerate its oncology pipeline, including lead bispecific antibody CR-001 and novel ADCs.
GlycoMimetics, Inc. stockholders have overwhelmingly approved the proposed merger with Crescent Biopharma, Inc., along with a significant 1-for-100 reverse stock split and other key proposals, paving the way for the combined entity to trade as Crescent Biopharma, Inc. under the new ticker CBIO.
GlycoMimetics, Inc. has filed supplemental disclosures to its Form 8-K, providing further details on its proposed reverse merger with Crescent Biopharma, Inc., which includes a planned $125 million concurrent PIPE financing and an $8 million enterprise valuation for GlycoMimetics.
GlycoMimetics, Inc. has amended its merger agreement with Crescent Biopharma, Inc. to clarify the treatment of restricted stock units and voting mechanics related to the merger.
GlycoMimetics, Inc. announces the termination of its collaboration agreement with Apollomics, along with the resignation of key executives and board members, amidst a proposed transaction with Crescent Biopharma.
GlycoMimetics amends its merger agreement with Crescent Biopharma, adjusting financing structure and SEC filings while maintaining the expected exchange ratio and ownership percentages.
GlycoMimetics' CEO and CFO have announced their intention to leave the company by March 31, 2025, prior to the expected closing of the merger with Crescent Biopharma, Inc.
8-K: GlycoMimetics and Crescent Biopharma Update Merger Presentation, Highlighting Oncology Pipeline
GlycoMimetics and Crescent Biopharma updated their investor presentation regarding their proposed merger, focusing on Crescent's oncology pipeline and development plans.
GlycoMimetics has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement and has been transferred to the Nasdaq Capital Market.
GlycoMimetics and Crescent Biopharma have updated their investor presentation regarding their proposed merger, highlighting Crescent's pipeline and financial projections.
GlycoMimetics will acquire Crescent Biopharma, a private oncology company, in an all-stock transaction supported by a $200 million private placement, aiming to advance Crescents pipeline of novel biologics.
GlycoMimetics is initiating a strategic review and restructuring, including an 80% workforce reduction, after the FDA indicated that an additional clinical trial would be required for its lead drug candidate.
GlycoMimetics has been notified by Nasdaq that it is not in compliance with listing rules due to its stock price falling below $1.00 for 30 consecutive days.
GlycoMimetics has granted performance-based stock options to its named executive officers, vesting upon FDA approval of uproleselan for acute myeloid leukemia.
8-K: GlycoMimetics Announces Positive Phase 3 Trial Results for Uproleselan in Primary Refractory AML
GlycoMimetics' Phase 3 trial of uproleselan shows a significant improvement in overall survival for patients with primary refractory acute myeloid leukemia.
GlycoMimetics' Phase 3 trial of uproleselan in relapsed/refractory acute myeloid leukemia did not meet its primary endpoint of overall survival, though the company plans to present a comprehensive data analysis at an upcoming medical meeting.
8-K: GlycoMimetics Stockholders Approve Increase in Authorized Shares and Officer Liability Protection
GlycoMimetics' stockholders approved an increase in authorized shares and a provision limiting officer liability at the 2024 Annual Meeting.
GlycoMimetics reports its 2023 financial results, highlighting progress in clinical trials for uproleselan and GMI-1687, with topline results for a pivotal Phase 3 study expected in Q2 2024.
GlycoMimetics is advancing its clinical programs, including a Phase 3 trial for uproleselan in relapsed/refractory AML with topline results expected in Q2 2024, and a Phase 2 trial in front-line AML.